Related Experiment Video

Updated: Sep 20, 2026

Induction and Testing of Hypoxia in Cell Culture
07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth

Lakshman Gunaratnam1, Melissa Morley, Aleksandra Franovic

  • 1Department of Cellular and Molecular Medicine and Kidney Research Center, Faculty of Medicine, University of Ottawa, Ontario, Canada.

The Journal of Biological Chemistry
|August 29, 2003
PubMed

Insights

Loss of the VHL gene in kidney cancer leads to overproduction of TGF-alpha via HIF, driving cell growth through the EGF-R pathway. This highlights HIF

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Bi-allelic mutations in the VHL tumor suppressor gene are prevalent in clear cell renal cell carcinoma (RCC).
  • VHL-deficient RCC cells exhibit constitutive activation of hypoxia-inducible factor (HIF) due to oxygen-independent pathways.
  • The precise role of HIF in VHL-deficient RCC oncogenesis and uncontrolled proliferation is not fully understood.

Purpose of the Study:

  • To investigate the role of HIF in the unregulated growth of VHL-deficient clear cell renal cell carcinoma (RCC) cells.
  • To determine the specific pathways and molecular mechanisms by which HIF contributes to RCC cell proliferation.
  • To elucidate the relationship between VHL status, HIF activity, and growth factor signaling in RCC.

Main Methods:

  • Utilized dominant-negative HIF and EGF-R inhibitors to assess pathway involvement.
  • Analyzed the expression profile of EGF-R ligands, specifically TGF-alpha, in relation to VHL and HIF status.
  • Restored VHL function in VHL-deficient RCC cells to observe effects on TGF-alpha production and proliferation.

Main Results:

  • HIF plays a critical role in promoting VHL(-/-) RCC cell growth by activating the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor receptor (EGF-R) pathway.
  • Inhibition of HIF or EGF-R effectively blocked EGF-R activation and serum-independent growth of VHL(-/-) RCC cells.
  • TGF-alpha was identified as a key HIF target responsible for driving proliferation, unlike other HIF targets such as VEGF.
  • Restoration of VHL function normalized TGF-alpha production and inhibited proliferation in serum-free media.

Conclusions:

  • Constitutive HIF activation in VHL(-/-) RCC cells drives oncogenesis through the TGF-alpha/EGF-R pathway.
  • TGF-alpha acts as a crucial mitogen in VHL-deficient RCC, mediating HIF-driven proliferation.
  • These findings suggest a broader role for HIF in cancer development than previously recognized, implicating it as a significant driver of renal cell carcinoma growth.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...